Albutrepenonacog alfa is a recombinant Factor IX fused to recombinant human albumin used to treat hemophilia B. It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017.
- Mechanism
- Curator reviewed · 3 references
The current therapies against hemophilia B are hampered by the short half-life of the replacement FIX therapy. Thus, to solve this problem, in rIX-RFP there is the fusion of rFIX with rAlbumin which presents a much longer half-life and it does not present interactions with the immune system.
The administration of rIX-RFP increases the plasma concentration of FIX, thus addressing the coagulation deficiency of the patient. rIX-RFP is able to circulate in the plasma as an intact zymogen thanks to the pH-dependent binding to FcRn which is a normal protection pathway from lysosomal degradation of albumin. When the FIX is needed, rAlbumin is cleaved by the same proteases that activate the FIX.
- Primary indication
- Under the EMA and FDA, rIX-RFP is indicated in the treatment of hemophilia B.Curator reviewed · 3 structured indications
- Formula / weight
- C5077N7846O1588PS67 · 125000.0 Da
- First approval
- Canada, 2016 · United States, 2016 · European Union, 2017
- Also known as
- Coagulation factor IX (recombinant), albumin fusion protein · Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
- Code names
- CSL-654
- Brand names
Resolves to
What you can answer from here — as of October 01, 2026
Which drugs share a target with Albutrepenonacog alfa, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account